Aprea Reports Cash of $46.5M, Sufficient to Support Operations into Q1 2028
As of March 31 the Company reported cash and cash equivalents of $46.5M compared to $14.6M as of December 31, 2025. The Company believes that its cash will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the Q1 of 2028. "We are very encouraged by the progress made across both our clinical and corporate priorities during the first quarter of 2026, including two partial responses observed in the ACESOT-1051 trial evaluating APR-1051. One of these has been confirmed at a second imaging assessment and this patient remains on study," said Oren Gilad, President and CEO of Aprea. "These efficacy results, coupled with the encouraging tolerability, support our precision medicine strategy and reinforce the potential of targeted therapies for patients who have limited treatment options. We look forward to presenting an update from ACESOT-1051 at ASCO 2026 and providing additional insight into APR-1051's emerging clinical profile. The recent $30 million private placement significantly strengthens our balance sheet and enables us to meaningfully expand patient enrollment, generating the clinical data needed to inform the future clinical path for APR-1051. We are grateful for the trust and support of both new and existing investors, whose participation reflects confidence in our development strategy and the potential of our programs."
